QuantuMDx and Menarini Announce an Exclusive Distribution Agreement for the Q-POC™ Platform

QuantuMDx Group Limited (“QuantuMDx”), a UK-based developer of transformational Point-of-Need molecular diagnostics, and A.Menarini Diagnostics S.r.I. (Menarini), are pleased to announce an exclusive distribution agreement for QuantuMDx’s Q-POC™ platform in the UK and France.

Under the terms of the agreement, Menarini will market, sell and service Q-POC™, QuantuMDx’s SARS- CoV-2 assay and its new SARS-CoV-2, Flu A/B, RSV Respiratory Panel test which the Company launched earlier this year. The five-year agreement will initially cover distribution to the UK and France, with the scope to expand to other markets.

Jonathan O’Halloran, Chief Executive Officer, QuantuMDx, said: “This agreement with Menarini is a significant commercial step for QuantuMDx. Not only does Menarini have a vast global network, but their specific in-country knowledge and presence across Europe, and beyond, means they are an excellent partner for us. The agreement will allow us to further accelerate commercial sales of Q- POC™, bringing our Point-of-Need multiplex molecular diagnostics platform to clinical and non-clinical settings in a host of new markets. I look forward to working closely with Menarini on what I am confident will be a very successful partnership.”

Fabio Piazzalunga, Global Head, Menarini Diagnostics S.r.I., commented: “The recent pandemic has highlighted the importance of being able to accurately, and rapidly, diagnose infectious diseases. QuantuMDx’s Q-POC™ platform, which can provide results in approximately 30 minutes, will allow healthcare professionals to make informed treatment decisions and slow the risk of transmission. Menarini is a pioneer in decentralising diagnostics routines and developed core competencies and technologies in doing so. We are extremely happy to be able to start providing such an innovative platform to laboratories in the UK and France.”